Navigation Links
Bioniche Pharma and Synerx Pharma Launch Fomepizole Injection
Date:9/24/2009

LAKE FOREST, Ill., Sept. 24 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, and Synerx Pharma, LLC, announced today the launch of Fomepizole Injection, the generic equivalent of Antizol(R) from Paladin Labs, Inc.

(Logo:http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"The addition of Fomepizole to Bioniche's product offering further broadens our base of niche injectables," said George Zorich, President, US Operations for Bioniche Pharma.

Bioniche Pharma and Synerx Pharma entered into a definitive agreement whereby Bioniche Pharma has the rights to market and distribute Fomepizole in the United States.

Bioniche will supply Fomepizole Injection in 1.5g /1.5 mL vials.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets. The company's growth is fueled by an internal development pipeline and an aggressive acquisition strategy for products. Bioniche Pharma was acquired in February 2006 by RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois. More information about Bioniche Pharma can be found at www.bionichepharma.com.

About Synerx Pharma:

Synerx Pharma, LLC is a privately held corporation located in historic Bucks County Pennsylvania. Established in January 2004, the company develops and brings to market select pharmaceutical products aimed at addressing unmet market needs, particularly those involving some combination of barriers to entry. The company focuses on developing cost effective specialty generic pharmaceuticals and small brand products. Synerx presently has six FDA approved products, of which four were First Time Generic Approvals, and a development portfolio of ten projects at various stages of development in multiple dosage forms. More information can be found at www.synerxpharma.com.

Antizol(R) is a registered trademark of Paladin Labs.


'/>"/>
SOURCE Bioniche Pharma
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Bioniche Reports Fiscal 2009 Year-End Results
2. Bioniche Phase III Clinical Trial with Urocidin(TM) Given Continued Green Light by DMC
3. Bioniche Repays Revolving Credit Facility
4. Bioniche Provides a Corporate Update
5. Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection
6. Bioniche Represented at House of Commons Sub-Committee on Food Safety
7. Bioniche Phase III Clinical Trial with Urocidin(TM) Progressing Well
8. Bioniche Reports Fiscal 2009 Third Quarter
9. Bioniche Provides a Corporate Update
10. Bioniche Completes Recruitment in First Phase III Clinical Trial with Urocidin(TM)
11. Bioniche Revolving Credit Facility Maturity Date Amended
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... (PRWEB) , ... March 27, 2017 , ... ... ability to gain site attention and engagement over the household brands of Top-20 ... webinar will discuss how partnering with the right outsourcing payments provider can ...
(Date:3/27/2017)... , ... March 27, 2017 , ... A study by ... MD, and his colleague, Sudeep Roy, MD, was recently published in the American ... Efficacy in Rhytidectomy” details Drs. Buckingham and Roy’s study on the use of Electro ...
(Date:3/27/2017)... ... March 27, 2017 , ... Buzzies parent company, The TouchPoint Solution’s ... the Runway Foundation and UBS’ Project Entrepreneur. Mayo will present her pitch about the ... , Project Entrepreneur’s second annual venture competition ignites bold ideas by providing women access ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... CE Certificate of Conformity for the Smart System® 20/20. CE Certification builds upon ... industry standards and specifications such as ANSI, ISO and proven test methods used ...
(Date:3/27/2017)... NJ (PRWEB) , ... March 27, 2017 , ... ... of cutting-edge news, research and conference coverage on veterinary medicine, announces the launch ... inaugural issue will be packaged with the April edition of American Veterinarian™. ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... British Columbia , March 27, 2017 ... Directors has appointed William "Bill" Dubiel as President and ... was also elected to the Board of Directors of ... as the Executive Chairman of LightIntegra. ... LightIntegra,s next President and Chief Executive Officer. We,ve selected ...
(Date:3/27/2017)... -- A new survey from the American Association ... Program (CBP) significantly reduced beneficiary choice and access to ... forces beneficiaries to switch to unfamiliar or unsuitable testing ... AADE,s survey is the latest in a continuous ... the inherent problems with the CBP. Last year, a ...
(Date:3/27/2017)... 2017 BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... that AGI-134, an immunotherapy for the treatment of multiple cancers, ... be featured at the upcoming American Association for Cancer ... to be held on April 1-5, 2017. ... An abstract ...
Breaking Medicine Technology: